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Background: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular
endothelial growth factor receptors 1, 2, and 3 in combination with pemetrexed and cisplatin was evaluated in
patients with advanced non-squamous non–small-cell lung cancer (NSCLC).
Methods: Overall, 170 patients were randomly assigned to receive axitinib at a starting dose of 5-mg twice daily
continuously plus pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of up to six 21-day cycles (arm I); axitinib
on days 2 through 19 of each cycle plus pemetrexed/cisplatin (arm II); or pemetrexed/cisplatin alone (arm III). The
primary endpoint was progression-free survival (PFS).
Results: Median PFS was 8.0, 7.9, and 7.1 months in arms I, II, and III, respectively (hazard ratio: arms I vs. III, 0.89
[P = 0.36] and arms II vs. III, 1.02 [P = 0.54]). Median overall survival was 17.0 months (arm I), 14.7 months (arm II), and
15.9 months (arm III). Objective response rates (ORRs) for axitinib-containing arms were 45.5% (arm I) and 39.7% (arm II)
compared with 26.3% for pemetrexed/cisplatin alone (arm III). Gastrointestinal disorders and fatigue were frequently
reported across all treatment arms. The most common all-causality grade ≥3 adverse events were hypertension in
axitinib-containing arms (20% and 17%, arms I and II, respectively) and fatigue with pemetrexed/cisplatin alone (16%).
Conclusion: Axitinib in combination with pemetrexed/cisplatin was generally well tolerated. Axitinib combinations
resulted in non-significant differences in PFS and numerically higher ORR compared with chemotherapy alone in
advanced NSCLC.
Trial registration: ClinicalTrials.gov: NCT00768755 (October 7, 2008).
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Currently, the majority of patients with non–small-cell
lung cancer (NSCLC) present with inoperable, locally
advanced (stage IIIB) or metastatic (stage IV) disease for
which no curative therapy is available, and the 5-year sur-
vival rate has remained ≤5% for the last few decades [1,2].
In patients with advanced or metastatic NSCLC without
certain cytogenetic abnormalities (e.g. epidermal growth
factor receptor [EGFR] mutations, anaplastic lymphoma
kinase [ALK] translocations), platinum-based doublet* Correspondence: cbelani@hmc.psu.edu
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unless otherwise stated.chemotherapy remains the standard of care, albeit with
modest efficacy [3], necessitating the search for additional
treatment approaches to improve clinical outcomes. Be-
cause angiogenesis plays a critical role in tumor survival,
growth, and metastasis, inhibition of the key angiogenesis
pathway mediated via vascular endothelial growth factor
(VEGF)/VEGF receptor signaling, either at the ligand level
(e.g. bevacizumab) or at the receptor level (e.g. the tyro-
sine kinase inhibitors [TKIs] sorafenib, sunitinib, pazopa-
nib, or axitinib, among many others), has been intensively
evaluated in advanced NSCLC [4,5]. Addition of bevacizu-
mab to paclitaxel and carboplatin was shown to improve
overall survival (OS) compared with chemotherapy alone
in patients with advanced non-squamous NSCLC, providingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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genic agent with chemotherapy [6]. However, the extent
of survival gained from the addition of bevacizumab to
chemotherapy may still be considered modest.
Axitinib is a potent and selective second-generation in-
hibitor of VEGF receptors 1, 2, and 3 [7] approved in the
United States, European Union, Japan, and elsewhere for
the treatment of advanced renal cell carcinoma after fail-
ure of one prior systemic therapy. Axitinib also showed
promising single-agent activity with an acceptable safety
profile in an open-label, single-arm, phase II trial in
advanced NSCLC [8]. In treatment-naïve (n = 9) and
previously treated (n = 23) patients with advanced
NSCLC, objective response rate (ORR) was 9%, with
median progression-free survival (PFS) and OS of 4.9
and 14.8 months, respectively. Common adverse events
(AEs) included fatigue, anorexia, diarrhea, nausea, and
hypertension. Axitinib was also generally well tolerated
when administered in combination with standard chemo-
therapy in patients with advanced solid tumors, including
NSCLC [9], which is the basis for the current study.
This study was undertaken to evaluate the efficacy and
safety of combining axitinib with the pemetrexed/cisplatin
regimen compared with pemetrexed/cisplatin alone in pa-
tients with advanced or recurrent non-squamous NSCLC.
The choice of backbone chemotherapy was based on a
large prospective phase III trial [10] that demonstrated OS
superiority with better tolerability of pemetrexed/cisplatin
over that of cisplatin/gemcitabine in NSCLC. In addition,
axitinib was administered in two different dosing schedules
(continuously vs. intermittently) to investigate whether a
2-day break in axitinib dosing just prior to chemotherapy
administration would improve efficacy.
Methods
Patients
Patients aged 18 years and older (≥20 years in Japan)
with histologically or cytologically confirmed stage IIIB
with malignant pleural or pericardial effusion, stage IV,
or recurrent non-squamous NSCLC were eligible. Add-
itional inclusion criteria included at least one measur-
able target lesion as defined by Response Evaluation
Criteria in Solid Tumors (RECIST v1.0); adequate bone
marrow, hepatic, and renal function; Eastern Coopera-
tive Oncology Group performance status (ECOG PS) 0
or 1; and no evidence of uncontrolled hypertension
(blood pressure [BP] >140/90 mmHg). Antihypertensive
medications were allowed. Exclusion criteria included
prior systemic therapy for stage IIIB or IV or recurrent
NSCLC; prior treatment with a VEGF or VEGF-receptor
inhibitor; lung lesion with cavitation, or invading or
abutting a major blood vessel; hemoptysis (>2.5 mL in
any 24-hr period) <2 weeks before enrollment; National
Cancer Institute Common Terminology Criteria forAdverse Events (CTCAE, v3.0) Grade 3 hemorrhage
(from any cause) <4 weeks before enrollment; untreated
central nervous system metastases; regular use of anti-
coagulants; or current use or anticipated need for cyto-
chrome P450 (CYP) 3A4-inhibiting or CYP3A4- or
CYP1A2-inducing drugs. Each patient provided written
informed consent before study entry.Study design and treatment
This was a randomized, multicenter, open-label phase II
study conducted in 37 centers in 11 countries, and the
primary endpoint was PFS assessed by investigators. A
non-randomized phase I lead-in (n = 10) evaluated the
pharmacokinetics and safety of axitinib 5 mg oral dose
twice daily (bid) given continuously with pemetrexed
500 mg/m2 and cisplatin 75 mg/m2 administered once
every 21 days [11].
In phase II, eligible patients were stratified by gender
and ECOG PS (0 vs. 1) and, using a centralized, random-
ized permuted block allocation within strata generated by
the central randomization administrator, assigned (1:1:1)
to receive axitinib bid continuously plus pemetrexed/cis-
platin (arm I), axitinib in a modified-dosing schedule plus
pemetrexed/cisplatin (arm II), or pemetrexed/cisplatin
alone (arm III). Axitinib was administered orally at a start-
ing dose of 5 mg bid in 21-day cycles. For the modified-
dosing schedule (arm II), axitinib was given on days 2
through 19, followed by a 3-day interruption (i.e. 2 days
before and the day of chemotherapy), except the last cycle,
during which it was given on days 2 through 21. Axitinib
dose could be increased step-wise to 7 mg bid, and then
to a maximum of 10 mg bid, in patients who tolerated
axitinib with no treatment-related CTCAE Grade ≥3 AEs
for ≥2 weeks, unless BP was greater than 150/90 mmHg
or patient was taking antihypertensive medication. Axi-
tinib dose was reduced step-wise to 3 mg bid, and then to
2 mg bid, at the discretion of the investigator, in patients
who experienced a treatment-related CTCAE Grade 3 AE
or BP >150/100 mmHg on maximal antihypertensive
treatment. Axitinib treatment was temporarily interrupted
in patients who had a treatment-related CTCAE Grade 4
AE, BP >160/105 mmHg, or urine protein/creatinine ra-
tio ≥2.0 and restarted at the next lower dose once im-
proved to CTCAE Grade ≤2, BP <150/100 mmHg, or
urine protein/creatinine ratio <2.0, respectively. If a pa-
tient required a dose reduction below 2 mg bid, axitinib
was to be discontinued. Pemetrexed 500 mg/m2 and cis-
platin 75 mg/m2 were administered intravenously on
day 1 of each of up to six 21-day cycles. Dose reductions
were based on nadir hematologic counts or maximum
non-hematologic toxicity from the preceding cycle. Vitamin
B12 (1000 μg) and folic acid (350–1000 μg) were adminis-
tered ≥1 week prior to treatment and then every 9 weeks
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chemotherapy.
Patients randomized to arms I and II who completed
four to six cycles of axitinib plus pemetrexed/cisplatin
and had stable disease or better continued to receive
single-agent axitinib maintenance therapy until disease
progression, unacceptable toxicity, or withdrawal of
patient consent. All patients were followed bimonthly
for survival status following discontinuation of study
treatment until at least 1 year after randomization of
the last patient. Crossover between treatment arms was
not allowed.
The study protocol was reviewed and approved by the
institutional review board or independent ethics commit-
tee at each center. The names of all institutional review
boards and independent ethics committees are listed under
Appendix. The study was conducted in compliance with
the Declaration of Helsinki, International Conference
on Harmonization Good Clinical Practice Guidelines,
and local regulatory requirements. This trial was registered
at ClinicalTrials.gov (NCT00768755) on October 7, 2008.
Assessments
Radiologic tumor assessments were performed at screen-
ing and every 6 weeks thereafter, and whenever disease
progression was suspected. Responses were evaluated ac-
cording to RECIST and required confirmation ≥4 weeks
after initial documentation. Safety was evaluated through-
out the study. BP measurements were taken at screening
and on day 1 of each cycle and thyroid function tests were
conducted at screening and on day 1 of each chemother-
apy cycle (cycles 1–6) and on day 1 of every other cycle
thereafter. In addition, patients in arms I and II self-Patients random
(n = 170; intent-to-trea
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Figure 1 Summary of patient disposition. AE, adverse event.monitored BP bid at home prior to axitinib dosing
and were instructed to contact their physicians for fur-
ther evaluation of systolic BP >150 mmHg or diastolic
BP >100 mmHg. Patient-reported outcomes (PROs) were
evaluated, using the M. D. Anderson Symptom Inventory
(MDASI) questionnaire on days 1 and 8 of each chemo-
therapy cycle and on day 1 of each axitinib maintenance
cycle. MDSAI is a 19-item, validated self-reported ques-
tionnaire consisting of two scales that assess symptom se-
verity and interference with different aspects of patient’s
life [12]. Mean change in the MDASI score ≥0.98 point
was defined as clinically meaningful.
Statistical analysis
The primary purpose of this study was to assess the effi-
cacy (as measured by PFS) of axitinib in combination with
pemetrexed/cisplatin versus pemetrexed/cisplatin alone in
patients with non-squamous NSCLC in the randomized
phase II study. The sample size estimates were based on
separate comparisons of the axitinib-containing arms I
and II versus arm III (pemetrexed/cisplatin alone). Fifty
patients were required in each arm and 70 events for each
comparison for a two-sample log-rank test to have an
overall one-sided significance level of 0.20 and power of
0.80. This assumed a 50% improvement in median PFS
from 5.0 months in arm III to 7.5 months in arm I or II,
and ~12-month accrual time and 6-month follow-up. The
hazard ratio and its 95% CI were estimated. A stratified
log-rank test (one-sided, α = 0.20) was used to compare
PFS between the treatment arms; however, the P values
were for reference only.
Secondary endpoints included OS, ORR, duration of
tumor response, PROs, and safety. ORR between treatmentized
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Table 1 Baseline patient demographics and clinical
characteristics
Demographics
or Clinical
characteristics
Arm I: Axitinib
(Continuous) +
Pem/Cis
Arm II: Axitinib
(Modified) +
Pem/Cis
Arm III:
Pem/Cis
Alone
n = 55 n = 58 n = 57
Age, yr, median (range) 62 (30–77) 62 (35–83) 59 (42–76)
Gender, n (%)
Male 34 (62) 37 (64) 37 (65)
Female 21 (38) 21 (36) 20 (35)
Race, n (%)
White 39 (71) 49 (84) 45 (79)
Black 0 1 (2) 0
Asian 15 (27) 8 (14) 12 (21)
Other 1 (2) 0 0
Smoking status,
n (%)
Never smoked 15 (27) 9 (16) 12 (21)
Smokera 40 (73) 49 (84) 45 (79)
ECOG PS, n (%)
0 25 (45) 25 (43) 27 (47)
1 30 (55) 33 (57) 28 (49)
Not reported 0 0 2 (4)
Histological classification,
n (%)
Adenocarcinoma 53 (96) 52 (90) 47 (82)
Large cell 1 (2) 3 (5) 8 (14)
Bronchioloalveolar 0 2 (3) 2 (4)
Other 1 (2) 1 (2) 0
Disease stage at
baseline, n (%)
Stage IIIB 3 (5) 6 (10) 4 (7)
Stage IV 46 (84) 50 (86) 52 (91)
Recurrent 6 (11) 2 (3) 1 (2)
Prior therapy, n (%)
Resectionb 14 (25) 12 (21) 16 (28)
Radiation 11 (20) 7 (12) 8 (14)
Abbreviations: Pem/Cis Pemetrexed/cisplatin, ECOG PS Eastern Cooperative
Oncology Group performance status.
aIncluded both active and ex-smokers.
bIncluded partial resection.
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stratified by baseline ECOG PS and gender. Descriptive
summary statistics (mean with standard deviation of abso-
lute scores and mean change from baseline with 95% CI)
of the MDASI items were reported. Safety was analyzed in
patients who received at least one dose of study drug, and
the results from only the randomized phase II portion were
presented here.
The efficacy and safety analyses were originally con-
ducted based on the data obtained as of March 1, 2011,
while the study was still ongoing. PFS and overall safety
were later updated using a data cutoff date of December
21, 2011, which are presented here. It should be noted
that median PFS in each arm were very similar between
the two analyses. The final analysis for OS, duration of
tumor response among responders, number of deaths,
and serious AEs was conducted after the database lock
on May 18, 2012. For each endpoint, the most-up-to
date results are presented in this manuscript.
Results
Patient characteristics
Between January 19, 2009 and April 21, 2010, a total of
170 patients were randomly assigned among three treat-
ment arms: arm I (n = 55), arm II (n = 58), and arm III
(n = 57; Figure 1). All patients were treated with
assigned drugs, except two patients in arm III who did
not receive pemetrexed/cisplatin. Among patients across
the three treatment arms, the median age was similar
(Table 1). The majority of patients were white (range, 71–
84%) and male (range, 62–65%), and diagnosed with stage
IV NSCLC (range, 84–91%). Smokers (both current and
former) comprised 73%, 84%, and 79% of patients in arms
I, II, and III, respectively.
Treatment
The median number of cycles for pemetrexed and cis-
platin was similar across all treatment arms: five cycles
each in arm I, six and five cycles, respectively, in arm II,
and six cycles each in arm III. The median (range) of
axitinib treatment cycles was 8 (1–28) in arm I and 6.5
(1–22) in arm II. Patients in arm I received axitinib
treatment longer than those in arm II (median days on
axitinib: 158 and 117 days, respectively). One or more
axitinib dose interruptions were reported in 87% of pa-
tients in arm I and 97% in arm II, of which 76% and
69%, respectively, were due to AEs. Median relative
axitinib dose intensity (defined as [total dose adminis-
tered/total dose assigned] × 100) was 92% in arm I and
104% in arm II. Median relative dose intensity was
similar between the three arms for pemetrexed (99%,
99%, and 100%) and for cisplatin (98%, 99%, and
100%). Following combination treatment, 58% of pa-
tients in arm I and 50% in arm II received single-agentaxitinib maintenance therapy. By the completion of the
study, all patients discontinued the study, mostly due
to death (n = 116; Figure 1).
Efficacy
The investigator-assessed median (95% CI) PFS was 8.0
(6.5–10.0), 7.9 (6.2–9.5), and 7.1 (5.8–9.2) months in
arms I, II, and III, respectively (Figure 2a). The hazard
ratio (95% CI) was 0.89 (0.56–1.42; P = 0.36) for arm I
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    HR (95% CI) = 1.45 (0.92–2.29)
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Figure 2 Kaplan-Meier estimates for (a) progression-free survival and (b) overall survival. P values were based on one-sided log-rank
test stratified by Eastern Cooperative Oncology Group performance status and gender. Progression-free survival was based on data cutoff date
of December 21, 2011 and overall survival was based on the most recent data at the time of final database lock on May 18, 2012. CI,
confidence interval; Cont, continuously; HR, hazard ratio; mod, modified schedule; mOS, median overall survival; mPFS, median
progression-free survival.
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versus arm III. Median OS (95% CI) was 17.0 (12.6–
22.5), 14.7 (11.5–18.1), and 15.9 (11.1–not estimable)
months in arms I, II, and III, respectively (Figure 2b).
Overall confirmed ORRs (95% CI) was 45.5% (32.0–59.4)
and 39.7% (27.0–53.4) for the axitinib-containing arms I
and II, respectively, which were both higher than the
26.3% (15.5–39.7) in arm III (Table 2). Median (95% CI)
duration of tumor response among responders was 7.8
(5.6–11.4), 6.7 (5.0–7.8), and 7.1 (4.2–24.7) months in
arms I (n = 25), II (n = 23), and III (n = 15), respectively.
Safety
Gastrointestinal disorders (nausea, vomiting, decreased
appetite, and constipation) and fatigue were common
treatment-emergent, all-causality AEs in all three treat-
ment arms (Table 3). Hypertension, diarrhea, and dys-
phonia occurred more frequently in axitinib-containing
arms compared with pemetrexed/cisplatin alone. Themost common Grade 3 AEs were hypertension in axitinib-
containing arms (20% in arm I and 17% in arm II) and
fatigue with pemetrexed/cisplatin alone (16%). Asthenia
and pulmonary embolism were the only Grade 4 AEs
observed in more than one patient in any arm (n = 2
each, arm II). Serious AEs reported by more than
three patients in any arm were vomiting, nausea, and
dehydration.
The majority of laboratory abnormalities reported during
the study were Grade 1 or 2. Abnormal neutrophil count
was the most common Grade 3/4 laboratory abnormality
among all three treatment arms (Table 3). Hypothyroidism
was reported infrequently (≤5%) in axitinib-containing
arms, and no severe hemorrhagic events occurred in any
treatment arm.
Patient-reported outcomes
At baseline, mean MDASI symptom severity (13-item
summary) and interference scores (6-item summary)
Table 2 Investigator-assessed best tumor responsea
Arm I: Axitinib
(Continuous) +
Pem/Cis
Arm II: Axitinib
(Modified) +
Pem/Cis
Arm III:
Pem/Cis
Alone
n = 55b n = 58 n = 57b
Best overall response,
n (%)
CR 0 0 0
PR 25 (45.5) 23 (39.7) 15 (26.3)
SD (≥8 weeks) 18 (32.7) 19 (32.8) 22 (38.6)
PD 4 (7.3) 7 (12.1) 8 (14.0)
Not assessed 0 1 (1.7) 1 (1.8)
Indeterminatec 7 (12.7) 8 (13.8) 9 (15.8)
Overall confirmed
ORR, n (%)
25 (45.5) 23 (39.7) 15 (26.3)
95% CI 32.0–59.4 27.0–53.4 15.5–39.7
Treatment
comparison, risk ratiod
(95% CI) vs. arm III
1.75 1.51 –
(1.05–2.94) (0.87–2.63) –
Pe 0.01 0.07 –
Abbreviations: Pem/Cis Pemetrexed/cisplatin, CR Complete response, PR Partial
response, SD Stable disease, PD Progressive disease, ORR Objective response
rate, CI Confidence interval.
aBased on data cutoff date of March 11, 2011.
bOne patient in arm I and two patients in arm III had no measureable disease
at baseline.
cPatients who did not have evaluable baseline scan or no post-randomization
scan or those who had stable disease for <8 weeks.
dCalculated based on a normal distribution.
eOne-sided Cochran-Mantel-Haenszel test stratified by Eastern Cooperative
Oncology Group performance status and gender.
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1.75, 2.09, and 1.80 and mean interference scores, 2.36,
2.97, and 2.64 in arms I, II, and III, respectively). Overall,
there were statistical increases in both mean symptom
severity and interference scores compared with baseline,
indicating some clinically meaningful worsening of symptom
severity and interference with patient feeling and func-
tion, in all three treatment arms. However, the majority
of absolute symptom severity and interference scores
remained <3.0 on a scale of 0 to 10.
Discussion
This study showed that axitinib, a selective antiangio-
genic TKI targeting VEGF receptors, in combination
with pemetrexed/cisplatin was generally well tolerated in
patients with advanced non-squamous NSCLC. However,
the study did not achieve its primary endpoint (PFS), irre-
spective of axitinib continuous or intermittent-dosing
schedules. In addition, although combination therapy re-
sulted in numerically higher ORR than chemotherapy
alone, it did not improve OS.
While cross-study comparison is complicated due to
many variables, median PFS and OS in patients treated
with pemetrexed/cisplatin alone in this study werelonger than the 4.8 and 10.3 months, respectively, ob-
served in a prior large phase III trial of pemetrexed/cis-
platin in chemotherapy-naïve NSCLC patients [10]. One
plausible explanation is the selection of patients with
non-squamous histology in the current study. Compared
with the previous study [10], this study also had a higher
percentage of Asians (21% vs. 13%), non-smokers (21%
vs. 15%), and patients with ECOG PS 0 (47% vs. 35%),
all of which have been identified as prognostic factors in
advanced NSCLC [13]. Another possible explanation for
longer survival in the control arm may be due to the
subsequent therapies. Although the percentage of pa-
tients in this study who received any follow-up systemic
therapy post-study, including EGFR inhibitors, was not
too different from that reported for patients who re-
ceived pemetrexed/cisplatin in the previous phase III
trial [10] (47% compared with 52.6%, respectively), no
data were available in either study to identify individuals
with genomic mutations in EGFR or ALK, who would
have benefited from the specific molecularly-targeted
follow-up therapy. It should also be noted that clinical
outcomes in a phase II study with a small number of pa-
tients do not always reflect the results of a subsequent
phase III study, as seen with other agents.
Since the Sandler et al. [6] landmark study demon-
strated significant survival benefits of adding bevacizumab
to platinum doublet chemotherapy, several antiangiogenic
TKIs have been evaluated in combination with cytotoxic
agents, but with generally disappointing results [14-16]. In
randomized phase III trials, addition of sorafenib to either
paclitaxel/carboplatin in chemotherapy-naïve patients
with advanced NSCLC [14] or gemcitabine/cisplatin in ad-
vanced non-squamous NSCLC [16] did not meet the pri-
mary endpoint of OS. In another recent phase III trial,
combination therapy with motesanib, another antian-
giogenic TKI, plus paclitaxel/carboplatin also failed to
prolong OS [15]. The current study of axitinib in com-
bination with pemetrexed/cisplatin adds to a growing
list of antiangiogenic TKIs that do not provide signifi-
cant survival benefits when combined with standard
doublet chemotherapy in advanced NSCLC, albeit with
acceptable toxicity.
Reasons for apparent failure of antiangiogenic TKIs to
improve efficacy of conventional chemotherapy are un-
clear, but are likely multifactorial and may include timing
of administering antiangiogenic agents relative to cyto-
toxic agents, as well as off-target activities of antiangio-
genic TKIs, adding to the toxicity. The potency of TKIs in
inhibiting VEGF receptors determined in vitro may not
necessarily translate to better efficacy in combination with
cytotoxic agents. It is postulated that bevacizumab induces
normalization of the tumor vasculature, thereby facilitating
uptake of cytotoxic agents [17,18]. In contrast, combin-
ation axitinib plus cyclophosphamide resulted in decreased
Table 3 Treatment-emergent, all-causality adverse events and laboratory abnormalities in ≥20% of patients in any
treatment arma
Adverse events,
n (%)
Arm I: Axitinib (Continuous) + Pem/Cis Arm II: Axitinib (Modified) + Pem/Cis Arm III: Pem/Cis Alone
All Grade All Grade All Grade
Grades 3/4 Grades 3/4 Grades 3/4
n = 55 n = 55 n = 58 n = 58 n = 55 n = 55
Nausea 38 (69) 10 (18) 30 (52) 3 (5) 33 (60) 4 (7)
Hypertension 37 (67) 11 (20) 28 (48) 10 (17) 6 (11) 0
Vomiting 29 (53) 8 (15) 19 (33) 3 (5) 16 (29) 2 (4)
Decreased appetite 28 (51) 4 (7) 28 (48) 4 (7) 23 (42) 2 (4)
Fatigue 27 (49) 6 (11) 25 (43) 9 (16) 25 (45) 9 (16)
Diarrhea 21 (38) 4 (7) 20 (34) 3 (5) 9 (16) 0
Constipation 20 (36) 0 15 (26) 1 (2) 23 (42) 1 (2)
Neutropenia 17 (31) 7 (13) 12 (21) 6 (10) 15 (27) 5 (9)
Dyspnea 13 (24) 3 (5) 14 (24) 2 (3) 10 (18) 3 (5)
Insomnia 13 (24) 0 8 (14) 1 (2) 11 (20) 0
Dysphonia 12 (22) 0 8 (14) 0 0 0
Cough 11 (20) 1 (2) 7 (12) 0 9 (16) 2 (4)
Headache 11 (20) 0 17 (29) 1 (2) 9 (16) 0
Anemia 7 (13) 3 (5) 20 (34) 8 (14) 23 (42) 6 (11)
Laboratory abnormalities, n/Nb (%)
Hyperglycemia 40/53 (75) 1/53 (2) 36/55 (65) 3/55 (5) 33/52 (63) 2/52 (4)
Hypoalbuminemia 26/50 (52) 1/50 (2) 31/54 (57) 1/54 (2) 23/50 (46) 0
Hypokalemia 23/53 (43) 0 17/55 (31) 1/55 (2) 10/52 (19) 0
Creatinine 22/54 (41) 2/54 (4) 29/55 (53) 5/55 (9) 24/53 (45) 3/53 (6)
Hyponatremia 18/54 (33) 3/54 (6) 18/55 (33) 7/55 (13) 11/52 (21) 1/52 (2)
Alkaline phosphatase 16/53 (30) 0 23/55 (42) 0 15/53 (28) 0
Hyperkalemia 16/53 (30) 2/53 (4) 26/55 (47) 2/55 (4) 19/52 (37) 2/52 (4)
ALT 15/53 (28) 1/53 (2) 23/55 (42) 1/55 (2) 12/53 (23) 2/53 (4)
Bicarbonate 8/30 (27) 0 17/38 (45) 1/38 (3) 13/39 (33) 0
AST 10/53 (19) 1/53 (2) 21/55 (38) 1/55 (2) 10/53 (19) 2/53 (4)
Abbreviations: Pem/Cis Pemetrexed/cisplatin, ALT Alanine aminotransferase, AST Aspartate aminotransferase.
aBased on data cutoff date of December 21, 2011.
bDenominator for each laboratory abnormality differed depending on the availability of baseline and at least one test result during the study treatment.
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oxy-cyclophosphamide) and decreased antitumor efficacy
in a preclinical study [19]. Based on [18F]fluorodeoxythy-
midine (FLT) positron emission tomography/computed
tomography imaging, continuous administration of axitinib
in patients with advanced solid tumors appears to reduce
the tumor uptake of FLT, which is reverted to baseline fol-
lowing axitinib dosing interruption [20,21]. Reduced FLT
uptake could indicate decreased tumor proliferation, but
also decreased cytotoxic drug delivery to the tumor, which
would reduce the activity of cytotoxic agents. In the
current study, it was hoped that stopping axitinib admin-
istration 2 days before and on the day of chemotherapy
would alleviate the latter effect of axitinib, but no im-
provement in efficacy was observed. Clearly, there is anurgent need for better understanding of the complex na-
ture of tumor angiogenesis and how axitinib and other
antiangiogenic TKIs affect not only the tumor vasculature
but also various cellular components within the tumor
microenvironment [22].
With regard to toxicity, addition of axitinib to standard
doses of pemetrexed and cisplatin did not lead to AEs
that were unexpected, based on studies with single-
agent axitinib [8] or pemetrexed/cisplatin alone [10] in
advanced NSCLC. Compared with chemotherapy alone,
incidence of hypertension increased substantially in pa-
tients receiving axitinib-containing treatment, which
has been observed with antiangiogenic agents in general
[16,23,24]. In the current axitinib-containing arms, no se-
vere hemorrhagic incidence was reported.
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http://www.biomedcentral.com/1471-2407/14/290Therefore, axitinib in combination with pemetrexed/
cisplatin was generally tolerable and AEs were manageable
in patients with advanced non-squamous NSCLC. Addition
of axitinib resulted in numerically higher ORR, but did not
improve PFS or OS compared with chemotherapy alone.
However, it remains to be seen if certain subsets of patients
may derive some benefits from the use of TKIs, in-
cluding axitinib, as reported for other TKIs in patients
with genomic abnormalities such as EGFR mutations
[25-27], crizotinib in ALK-positive NSCLC [28], or in
preclinical studies involving RET proto-oncogene rear-
rangements [29,30].
Conclusions
In patients with advanced non-squamous NSCLC, axitinib
in combination with pemetrexed plus cisplatin was gener-
ally well tolerated and resulted in numerically higher ORR
compared with chemotherapy alone. However, addition of
axitinib — continuous dosing or with a 3-day break around
the time of chemotherapy— did not improve PFS (primary
endpoint) or OS over chemotherapy alone.
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